SUPREP BOWEL PREP KIT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SUPREP BOWEL PREP KIT (SUPREP BOWEL PREP KIT).
SUPREP BOWEL PREP KIT contains sodium sulfate, potassium sulfate, and magnesium sulfate. These salts induce osmotic diarrhea by drawing water into the bowel lumen, thereby cleansing the colon. Magnesium sulfate also stimulates the release of cholecystokinin, which increases intestinal motility and secretion.
| Metabolism | Sodium, potassium, and magnesium sulfates are minimally metabolized; they are absorbed systemically in small amounts and excreted primarily renally. |
| Excretion | Primarily renal (sodium and sulfate are excreted unchanged in urine; negligible biliary/fecal elimination of active components). >90% of administered sodium and sulfate are excreted renally within 24 hours. |
| Half-life | Not applicable; sulfate is not metabolized and is eliminated with a half-life of approximately 7-9 hours in patients with normal renal function, but clinical effects are related to transit time rather than systemic half-life. |
| Protein binding | Negligible; sodium and sulfate are not significantly protein bound (<5%). |
| Volume of Distribution | Not applicable; components are primarily confined to the gastrointestinal lumen and not distributed systemically. For absorbed sulfate, Vd approximates extracellular fluid volume (~0.2 L/kg). |
| Bioavailability | Oral: near 0% for active laxative effect due to poor absorption; small amounts of sulfate may be absorbed (bioavailability <5% of ingested dose). |
| Onset of Action | Oral: first bowel movement typically occurs within 1-3 hours; complete colonic evacuation usually achieved within 3-5 hours. |
| Duration of Action | Evacuation effects last until bowel is cleared, generally 3-6 hours after last dose; residual effects may persist up to 12 hours. Drug is not absorbed and does not have systemic duration. |
Each SUPREP kit consists of two bottles. For colonoscopy preparation, administer one bottle (6 oz) mixed with 10 oz of water, followed by 16 oz of water or clear liquid. Administer second bottle 6-8 hours later, mixed with 10 oz of water, followed by 16 oz of water or clear liquid. For split-dose regimen: first bottle in the evening before procedure, second bottle on the morning of procedure.
| Dosage form | SOLUTION |
| Renal impairment | Contraindicated in patients with GFR <30 mL/min/1.73 m² due to risk of sodium phosphate nephropathy. For GFR 30-59 mL/min/1.73 m², use with caution; consider alternative bowel preparation. Not recommended in patients with impaired renal function or reduced creatinine clearance. |
| Liver impairment | No specific dose adjustment recommendations for hepatic impairment based on Child-Pugh classification. However, caution advised in patients with severe hepatic impairment due to potential fluid and electrolyte disturbances. |
| Pediatric use | Safety and efficacy not established in pediatric patients (<18 years). Not recommended. |
| Geriatric use | Elderly patients (>65 years) are at increased risk for fluid and electrolyte abnormalities, renal impairment, and adverse events. Use with caution; ensure adequate hydration. Consider alternative bowel preparation in frail elderly or those with comorbidities. No dose adjustment based solely on age. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SUPREP BOWEL PREP KIT (SUPREP BOWEL PREP KIT).
| Breastfeeding | Excretion unknown; use caution. M/P ratio not determined. |
| Teratogenic Risk | Category C: No fetal risk in animal studies; no adequate human studies. Avoid during pregnancy unless clearly needed. Risk of electrolyte imbalance may affect fetal development. |
| Fetal Monitoring | Monitor fluid and electrolyte balance; assess for dehydration. |
■ FDA Black Box Warning
None
| Serious Effects |
["Gastrointestinal obstruction or ileus","Gastric retention","Bowel perforation","Toxic colitis or toxic megacolon","History of gastric bypass or stapling surgery","Hypersensitivity to any component of the product"]
| Precautions | ["Risk of serious fluid and electrolyte disturbances; monitor for signs of dehydration","QT interval prolongation: caution in patients with preexisting electrolyte imbalances, those taking medications that prolong QT interval, or with history of arrhythmias","Renal impairment: increased risk of electrolyte abnormalities and seizure","Seizure risk: associated with electrolyte abnormalities, especially hyponatremia","Mucosal ulcerations: rare reports of aphthous ulcerations","Use in patients with impaired gag reflex, regurgitation, or aspiration: risk of aspiration pneumonia"] |
Loading safety data…
| Fertility Effects | No known effect on fertility. |